Cancer, Radiation Toxicity, Radiosensitivity
Conditions
Brief summary
Pre-therapeutic analysis of the individual radiosensitivity of cancer patients in Luxembourg
Interventions
BIOLOGICALBlood sample collection
Blood sample collection : 2 X 6 mL
Sponsors
BIONEXT
Neolys
Centre Francois Baclesse, Luxembourg
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years old * Patient with an indication for curative radiotherapy * Patient having given his signed written informed consent before any specific procedure of the protocol.
Exclusion criteria
* Patient with a contraindication to radiotherapy * Patient with an indication for palliative radiotherapy * Patient with a history of radiotherapy in the area where the cancer is located * Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validation of RadioDtect test on early radiation-induced toxicity | 3 months | prospectively validate the predictive capacities of the RadioDtect individual radiosensitivity blood test on early radiation-induced toxicity. The validation will be based on ATM protein assay and rate of acute toxicities of grade ≥ 2 to 3 months according to NCI-CTCAE v4.03 criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Validation of RadioDtect test on delayed radiation-induced toxicity | 12 months | to prospectively validate the predictive capacities of the RadioDtect individual. radiosensitivity blood test on delayed radiation-induced toxicity at 12 months. The validation will be based on ATM protein assay and rate of acute toxicities of grade ≥ 2 to 3 months according to NCI-CTCAE v4.03 criteria |
Contacts
Primary ContactGuillaume Vogin, MD PhD
Backup ContactCharlotte Lieunard
Outcome results
None listed